The following is a guest article by Brian Overstreet, President & CEO at Arbital Health
At a recent Summit on the Future of Value-Based Care (VBC) and Risk Contracting, more than 150 payer executives, provider leaders, policy influencers, and digital health innovators gathered to discuss the operational realities of managing risk. While the attendees represented organizations deeply committed to value-based care, their conversations revealed concern that the industry’s ambition for aligning financial returns to better patient outcomes is advancing faster than the infrastructure that supports that goal.
Three key themes emerged from the discussions at the event:
- Leaders are confident that VBC is working but are still having difficulty showing direct financial impact
- The first step in making value-based care succeed is actuarially scoring the value of clinical interventions so that the economics are clear
- AI’s value, cost, and long-term impact on VBC is still relatively unknown
Showing Direct Financial Impact
Despite momentum in the evolution of VBC, many organizations still struggle to measure results, particularly within a one-year contract cycle. Delayed performance data, misaligned measures, and slow operational processes make it hard to show financial impact on demand. Forecasting and risk adjustment are still not moving fast enough to support the industry’s ambitions.
Too many organizations are still relying on information cycles built for fee-for-service: lagged claims, quarterly refreshes, and retrospective reporting. In most risk contracts between payers and providers, that approach is no longer good enough.
The organizations gaining ground are not waiting for a settlement to understand performance. They are using actuarial AI to track performance trends against contract dynamics in real time, surface cost drivers earlier, and identify interventions before negative trends become financial results.
The First Step: Actuarially Scoring Clinical Interventions
Participants at the Summit described a practical formula for success in specialty value-based models:
- Actuarially score the value of clinical interventions, so the economics are clear
- Create meaningful provider incentives and engagement
- Deliver high-quality clinical care that improves patient outcomes
- Design benefits that reduce friction and drive patient participation
The first step—scoring interventions using actuarial logic—proved particularly important as it sets the stage for financial success, without which the rest becomes unsustainable. Too often, programs are launched with clinical enthusiasm but limited financial clarity and early measurability. Only actuaries can help set value against the counterfactual effects of VBC, i.e., the positive outcomes that didn’t happen (deaths avoided, etc.), versus those that did happen. Without actuarial modeling of potential outcomes, even well-intentioned and successfully executed interventions can struggle to demonstrate value within short contract windows.
The Debate Around AI
Healthcare organizations are investing heavily in AI, yet many executives are now asking if AI actually reduces costs, or if it is simply adding another layer of expense. Infrastructure investments, integration challenges, staffing requirements, and model maintenance can quickly accumulate for organizations trying to build AI solutions internally. And, for organizations already managing thin margins, the financial return on AI investments remains under scrutiny.
That skepticism is shaping how leaders evaluate new technologies. Tools that promise predictive insight are increasingly expected to deliver both operational efficiency and measurable financial impact.
A Shift Toward Actuarial AI
Most healthcare AI tools are built by data scientists trained to optimize predictions. What’s different about Actuarial AI is that it is built by actuarial engineers and trained on actuarial-grade logic — credibility theory, loss ratio modeling, risk adjustment mechanics, trend analysis, reserving principles, and regulatory guardrails – all tied to individual contract terms and measures. It does not “black box” outputs, but surfaces its assumptions, model logic, data sources, and calculations to be fully transparent and auditable.
That distinction matters because in risk contracting, trust is currency. If finance leaders cannot audit the model, they will not rely on it. At the Summit, participants discussed the shift from standard reporting to accountable analytics, that is, systems that show their math.
The Strategic Implications
VBC will continue expanding across Medicare Advantage, ACO REACH/LEAD Model, Medicaid managed care, and commercial risk arrangements, and the attendant complexity will increase. Organizations that pair actuarial expertise with actuarially engineered AI will price better, see performance trends faster, and provide actionable insight into bending the risk curve so that organizations can manage risk more confidently.
Industry leaders are optimistic about what comes next for VBC, both from a policy standpoint and in how it operates day-to-day, but they recognize that success will depend on more than expanding risk contracts.
Organizations seeking to move ahead will use AI to drive immediate efficiency and faster decision-making, while requiring transparency and auditability. The next phase of VBC will be defined not just by risk contracts, but by the intelligence infrastructure that supports them.
About Brian Overstreet
Brian Overstreet is the Co-Founder, President, and CEO at Arbital Health. Brian has over twenty years of experience working with data and analytics SaaS companies in the healthcare market.
No comments:
Post a Comment